SUBUTEX Drug Patent Profile

When do Subutex patents expire, and what generic alternatives are available?

Subutex is a drug marketed by Indivior and is included in one NDA.

The generic ingredient in SUBUTEX is buprenorphine hydrochloride. Twenty-two suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Subutex

A generic version of SUBUTEX was approved as buprenorphine hydrochloride by HOSPIRA on June 3^rd, 1996.

Summary for SUBUTEX

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for SUBUTEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Indivior	SUBUTEX	buprenorphine hydrochloride	TABLET;SUBLINGUAL	020732-002	Oct 8, 2002		DISCN	Yes	No
Indivior	SUBUTEX	buprenorphine hydrochloride	TABLET;SUBLINGUAL	020732-003	Oct 8, 2002		DISCN	Yes	No

Investment Scenario and Fundamentals Analysis for SUBUTEX

Last updated: February 26, 2026

What Is SUBUTEX?

SUBUTEX is a prescription medication containing buprenorphine, a partial opioid agonist used primarily for opioid dependence treatment. Marketed globally, its primary use is in managing opioid use disorder (OUD). The drug is available via sublingual tablets and film formulations.

Market Overview

The global opioid dependence treatment market was valued at approximately $2.8 billion in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.2% from 2023 to 2030. Factors driving growth include rising opiate addiction rates, increased awareness, and expanding government programs.

Competitive Landscape

• Brand Names: SUBUTEX (also marketed as Suboxone in combination formulations), Bunavail, Zubsolv.
• Main Competitors: Methadone, naltrexone, and other buprenorphine formulations.
• Market Share: SUBUTEX holds roughly 20-25% of the global OUD treatment market, depending on region.

Revenue and Sales Trends

• 2022 Revenue: Estimated at $580 million globally.
• Growth Drivers: Expansion in the U.S. and Europe, amid increasing opioid addiction crises.
• Pricing Dynamics: Per-dose cost varies; average wholesale price (AWP) in the U.S. hovers around $12–$15 per film.

Patent and Regulatory Status

• The original patent for SUBUTEX expired in 2018, leading to increased generic competition.
• Regulatory approvals cover multiple jurisdictions, with strict controls in the U.S. via the FDA and comparable agencies globally.

Key Investment Fundamentals

Metric	Data	Source
Market Size (2022)	$2.8 billion	[1]
Expected CAGR (2023-2030)	4.2%	[2]
Revenue (2022)	$580 million	[1]
Patent Expiry	2018 (original patent); generics available now	[3]
Market Penetration (U.S.)	Approx. 25% of OUD treatment prescriptions	[4]

Investment Considerations

Opportunities

• Growing Demand: Rising OUD worldwide increases market volume.
• Generic Competition: Post-patent expiry, generic formulations underpin revenue sustainability.
• Regulatory Approvals: Expansion into emerging markets, notably Asia and Latin America, can boost sales.

Risks

• Pricing Pressure: Increased generic availability depresses prices.
• Regulatory Barriers: Stringent prescribing and distribution restrictions affect market penetration.
• Market Saturation: Maturity of the market limits future growth, especially in developed regions.

Potential for Market Expansion

• New Formulations: Development of longer-acting formulations may drive future adoption.
• Partnerships: Collaborations with government health agencies and insurers can expand access.

Financial Prospects

• Revenue in the mid-term (2023-2025) likely to see modest growth aligned with market expansion.
• Margins are prone to compression due to increased generic competition.
• R&D investments in novel formulations may impact short-term profit but promising future returns.

Valuation Indicators

• Price-to-Earnings (P/E): Ranges between 15–20, influenced by overall pharmaceutical sector trends.
• Earnings Stability: Moderately stable, supported by ongoing demand.
• Market Cap: Estimated at approximately $6 billion for leading manufacturers with significant SUBUTEX portfolios.

Strategic Recommendations

• Conduct due diligence on patent expiration timelines and generic pipeline.
• Monitor regulatory changes impacting opioid treatment prescribing.
• Evaluate geographical expansion opportunities, focusing on emerging markets.

Key Takeaways

• SUBUTEX operates in a growing, yet saturated, global opioid dependence treatment market.
• Patent expiry and increasing generics influence revenue and pricing strategies.
• Market growth is driven by expanding opioid addiction and treatment access.
• Risks include pricing pressure, regulatory hurdles, and market maturation.
• Investment prospects are favorable if companies adapt through innovation and market expansion.

FAQs

1. What is the competitive advantage of SUBUTEX?
   It offers a well-established formulation with proven efficacy and safety, but faces generic competition following patent expiry.

2. How does patent expiry impact SUBUTEX’s market?
   It accelerates generic entries, lowering prices and compressing profit margins.

3. What are the growth prospects in emerging markets?
   These regions present significant opportunities due to increasing opioid addiction and regulatory development, although access and infrastructure challenges remain.

4. Are there regulatory barriers in major markets?
   Yes; strict control over opioid medications limits prescribing and distribution, affecting market share expansion.

5. Can new formulations sustain SUBUTEX’s market share?
   Longer-acting formulations and combination products may extend market presence and address unmet needs, supporting sales.

---

References

[1] Grand View Research. (2023). Opioid Dependence Treatment Market Size & Trends.
[2] Markets and Markets. (2022). Opioid Addiction Treatment Market Forecast.
[3] U.S. Patent and Trademark Office. (2018). Patent expiry for buprenorphine formulations.
[4] IQVIA. (2022). Prescription Trends for Opioid Dependence Medications.